MedTrace Logo

Chronic Subdural Hematoma and Aspirin

NCT03120182 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-05-13

No results posted yet for this study

Summary

The aim of this randomized, blinded, placebo controlled clinical study is to compare the peri- and postoperative bleeding and cardiovascular complication rates of patients undergoing burr-hole trepanation for chronic subdural hematoma with and without discontinuation of low-dose aspirin

Conditions

  • Chronic Subdural Hematoma

Interventions

DRUG

Acetylsalicylic acid

Patients will receive acetylsalicylic acid 100mg daily for 12 days after randomization

DRUG

Placebo Oral Tablet

Patients will receive placebo medication 100mg daily for 12 days after randomization

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Luigi Mariani, Prof, MD · Department of Neurosurgery, University Hospital Basel

  • Maria Kamenova, MD · Department of Neurosurgery, University Hospital Basel

  • Jehuda Soleman, MD · Department of Neurosurgery, University Hospital Basel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-19
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03120182 on ClinicalTrials.gov